BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2025-12-09
Target enrollment:
Participant gender:
Summary
This phase Ib trial finds out the best dose, possible benefits and/or side effects of
BAY1895344 and copanlisib in treating molecularly selected patients with solid tumors that
have spread to other places in the body (advanced). BAY1895344 and copanlisib may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving
BAY1895344 and copanlisib together may help control the progression of the disease in
patients with advanced solid tumors.